Only the tubular markers α 1 -MG and β 2 -MG were associated with eGFR independent of albuminuria, suggesting that they may play an important role in the development of DKD.
Material and methods:
A total of 252 type 2 diabetes patients and 50 nondiabetic controls from Tianjin, China, were selected. Diabetic patients were divided into three groups according to eGFR levels, including groups A, B, and C with eGFR ≥90 (n=94), 60-89 (n=94), and 30-59 (n=64) mL/min/1.73 m 2 . Urine levels of glomerular and tubular markers were detected in first morning urine samples, and their associations with eGFR and albuminuria analyzed.
Results: Urinary levels of IgG, TRF, and β2-MG were significantly elevated in diabetic patients with normal eGFR compared with nondiabetic control subjects. Urinary levels of all markers increased per eGFR stratum. All kidney damage markers were significantly associated with eGFR in univariate analysis (standard β between −0.35 and −0.28; all P<.001). After adjusting for known confounders, only the tubular markers α1-MG (standard β=−0.25; P=.013) and β2-MG (standard β=−0.18; P=.039) retained significant associations with eGFR. All kidney damage markers were significantly associated with albuminuria, independent of age, duration of diabetes, and eGFR (standard β between 0.45 and 0.86; all P<.001).
Conclusion:
Only the tubular markers α 1 -MG and β 2 -MG were associated with eGFR independent of albuminuria, suggesting that they may play an important role in the development of DKD.
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| INTRODUCTION
Diabetic kidney disease (DKD), the most common microvascular complication of diabetes mellitus (DM), is the leading cause of mortality and morbidity in DM patients. 1, 2 According to current relevant guidelines, early screening and staging of DKD is based on both albuminuria and the glomerular filtration rate (GFR). 3 Albuminuria and GFR are generally considered non-invasive markers for DKD detection 4 and independent risk factors for cardiovascular events. 5 Classically, albuminuria is considered a consequence of diabetes-induced glomerular damage, 6 and the glomerulus has attracted attention from scientists as the major site of injury in DKD. However, recent studies emphasize that tubulointerstitial damage might also play an important role in the pathophysiologic mechanisms implicated in DKD, especially in patients with type 2 diabetes. α1-microglobulin (α1-MG) and β2-microglobulin (β2-MG) are both low molecular weight proteins, and have been studied as markers of renal tubular dysfunction in various disorders. 8 Relatively few studies have assessed urinary α1-MG and β2-MG in diabetes, and these markers are not routinely used to diagnose and evaluate renal impairment in diabetic subjects. 9 Relatively, albuminuria is of higher interest than GFR, because by definition, low GFR identifies only patients at a late disease stage. 10 However, recent findings emphasize the importance of early change of GFR and appropriate intervention; specifically, early intervention can significantly delay the development of diabetic kidney damage.
11,12
The Japan Diabetes Clinical Data Management study found that in normoalbuminuric type 2 diabetic patients, 20% have renal decline as assessed by GFR. Therefore, to explore the associations of glomerular and tubular damage markers with DKD, GFR may be even more valuable.
In this study, we assessed the urinary levels of tubular damage markers (α1-MG and β2-MG) and glomerular damage markers (transferrin and immunoglobulin G) in diabetic patients based on eGFR stratum as well as nondiabetic control subjects. The aim of this study was to evaluate the associations of these markers with kidney disease severity, as assessed by estimated glomerular filtration rate (eGFR), while exploring their relationships with albuminuria.
| MATERIALS AND METHODS

| Study population
A total of 252 type 2 diabetes patients were enrolled at the and all participants provided written informed consent.
| Measurements
First morning urine and blood samples were obtained from subjects at clinical visits; meanwhile, medical history and anthropometric measurements were also recorded. Blood and urine samples were tested in our clinical laboratory department. All samples were stored at −80°C, thawed at room temperature, and centrifuged before use. Serum cystatin C (CysC) and urinary proteins were assessed by nephelom- 13 Meanwhile, ACR,
to-creatinie ratio (β2-MG/Cr), transferrin-to-creatinine ratio (TRF/ Cr), and immunoglobulin G-microglobulin-to-creatinine ratio (IgG/Cr) were calculated.
| Statistical analysis
Analyses were performed with SPSS 20.0 (IBM Corporation, Armonk, NY, USA). Data with skewed distribution were expressed as median and inter-quartile range, and normally distributed data as mean±SD.
Differences among groups were tested by ANOVA for normally distributed variables and Chi-square test for categorical variables. For non-normally distributed variables, Kruskal-Wallis test was used.
Logarithmic transformation of non-normally distributed variables was applied. Diabetic patients were divided into two groups, based on median cut-off values of urinary markers. Multivariate logistic regression analysis was used to evaluate the impact of clinical parameters on elevated urinary markers. We performed a linear regression analysis by using eGFR and ACR as dependent variables, respectively, and various damage markers as independent variables, to investigate the urinary markers related to eGFR and albuminuria.
P<.05 was considered statistically significant. Table 1 shows the baseline characteristics of all subjects. Compared with nondiabetic subjects, group B and C patients were slightly older and had lower level of eGFR; group C had higher prevalence of hypertension and increased level of diastolic blood pressure (DBP). Patients in groups C and B more often had a history of cardiovascular disease and lower levels of DBP and eGFR amounts, compared with group A individuals. Meanwhile, HbA1c levels were higher in groups A and C than in group B.
| RESULTS
The levels of damage markers in nondiabetic control subjects and diabetic patients are shown in Table 2 . β2-MG, IgG, and TRF amounts were higher in patients with diabetes of group A compared with values of nondiabetic control subjects. ACR and α1-MG levels were higher in patients with diabetes of group B than in control subjects; however, there were no statistically significant differences between group A and the control group. Meanwhile, the levels of all urinary damage markers increased with increasing amounts of eGFR in patients with diabetes. Figure 2 ). All the damage markers were positively correlated with albuminuria in univariate regression analysis (Table 4) . Meanwhile, albuminuria was correlated with age, duration of diabetes, eGFR. When these clinical parameters were entered into multivariate regression analyses, the urinary markers were still associated with albuminuria (Table 4) . 
T A B L E 1 Characteristics of nondiabetic control subjects (n=50) and diabetes patients (n=252) according to eGFR stratum
| DISCUSSION
Early decline of GFR is closely related to the incidence and development of kidney disease and cardiovascular events; therefore, early diagnosis and intervention to prevent or delay kidney damage and reduce end-stage renal disease as well as cardiovascular events has an important clinical significance. 14 In the current study, we assessed glomerular and tubular damage markers to explore their associations with the development of diabetic kidney disease as assessed by eGFR.
We found that urinary levels of glomerular and tubular damage mark- F I G U R E 2 Single regression analyses of urinary albumin-to-creatinine in relation to urinary IgG, transferrin (A and B) and α1-MG, β2-MG (C and D) respectively. Logarithm-transformed values were used for analysis. Regression lines are represented by a 95% confidence interval associated with eGFR after adjustment for albuminuria and other confounding factors.
In this study, urinary IgG and TFR levels were increased over the three eGFR groups, and negatively associated with eGFR in diabetic patients. The associations of glomerular damage markers (IgG, TFR) with DKD have been previously described, but most researches showed that the urinary levels of IgG and TFR paralleled the degree of urinary albumin excretion. In general, all investigated tubular markers were increased in higher eGFR strata. Few studies have, to date, investigated the associations of the tubular markers α 1 -MG and β 2 -MG with the severity of kidney injury in DKD assessed by eGFR. Urinary α 1 -MG was significantly increased in diabetic patients compared with normal subjects. 19 Urinary α 1 -MG plays an important role in predicting the progression of DN as suggested by increased albuminuria. 9, 20 Increased excretion of β 2 -MG was found in early disease course, while albumin excretion remained in the normal range in urine samples from diabetic patients. [20] [21] [22] In the current study, β 2 -MG levels were elevated in dia- In contrast, the levels of the tubular damage markers α 1 -MG and β 2 -MG remained associated with eGFR after adjusting for the above confounding factors. These data suggested that urinary α 1 -MG and β 2 -MG levels are promising markers for predicting the risk of DKD in addition to albuminuria.
In conclusion, the urinary levels of all the investigated damage markers were elevated in patients with diabetes compared with nondiabetic control subjects. These damage markers were associated with the severity of diabetic nephropathy as assessed by eGFR. Interestingly, some markers were already elevated in normal eGFR diabetic patients.
This suggested these proteins as potential sensitive markers for early diabetic kidney damage. Only the tubular markers α 1 -MG and β 2 -MG were negatively associated with eGFR independently of albuminuria, suggesting that α 1 -MG and β 2 -MG may play an important role in the development of DKD. Furthermore, measuring urinary α 1 -MG and β 2 -MG concentrations may be useful in assessing the severity of diabetic kidney damage in addition to measuring albuminuria. However, further longitudinal studies are required to fully assess the potential clinical use of these promising biomarkers in a larger population.
